Skip to content

Study · Non-randomized trial · 1997

5 results

Intrapulmonary drug delivery of salmon calcitonin.

Deftos LJ, Nolan JJ, Seely BL, Clopton PL, Cote GJ, Whitham CL, Florek LJ, Christensen TA, Hill MR

Calcified tissue international1 Oct 1997Cited by 17 (Europe PMC)

PMID9312206 (opens in a new tab)DOI10.1007/s002239900345 (opens in a new tab)PepBankPUB-09312206
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In normal subjects, inhaled salmon calcitonin produced significant hypocalcemia in all subjects.

    In plain wordsIn normal subjects, inhaled calcitonin significantly reduced blood calcium.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseHypocalcemia after inhalation
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    Dose not stated · intrapulmonaryAs given in this study (human).

    Source sentences

    Summary
    Inhaled SCT produced significant hypocalcemia in all subjects as did injected SCT, and the peptide could be readily measured in serum by immunoassay.
    3 context sentences
    Summary · context
    We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects.
    Summary · context
    SCT was administered with a dry powder delivery inhaler.
    Summary · context
    For comparison, each subject also received intramuscular (IM) SCT.
  2. 02HumanNon-randomized trialActivity measurement

    In normal subjects, injected salmon calcitonin produced significant hypocalcemia.

    In plain wordsIn normal subjects, injected calcitonin significantly reduced blood calcium.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseHypocalcemia after injection
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    Inhaled SCT produced significant hypocalcemia in all subjects as did injected SCT, and the peptide could be readily measured in serum by immunoassay.
    3 context sentences
    Summary · context
    We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects.
    Summary · context
    SCT was administered with a dry powder delivery inhaler.
    Summary · context
    For comparison, each subject also received intramuscular (IM) SCT.
  3. 03HumanNon-randomized trialPharmacokinetics

    In normal subjects, administered salmon calcitonin was readily measurable in serum by immunoassay.

    In plain wordsIn normal subjects, a blood test readily detected administered calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableSerum detection
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inhaled SCT produced significant hypocalcemia in all subjects as did injected SCT, and the peptide could be readily measured in serum by immunoassay.
    3 context sentences
    Summary · context
    We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects.
    Summary · context
    SCT was administered with a dry powder delivery inhaler.
    Summary · context
    For comparison, each subject also received intramuscular (IM) SCT.
  4. 04HumanNon-randomized trialActivity measurement

    In normal subjects, inhaled calcitonin had 66% of the dose-adjusted bioactivity of intramuscular calcitonin.

    In plain wordsIn normal subjects, inhaled calcitonin had lower activity per dose than injected calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseRelative bioactivity
    Study

    n: not reported in source

    Comparator
    intramuscular salmon calcitonin
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intrapulmonaryAs given in this study (human).

    Measurements

    Relative bioactivity
    66%
    versus IM

    Source sentences

    Summary
    Compared by dose, IP SCT had 66% of the bioactivity and 28% of the bioavailability of IM SCT.
    3 context sentences
    Summary · context
    We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects.
    Summary · context
    SCT was administered with a dry powder delivery inhaler.
    Summary · context
    For comparison, each subject also received intramuscular (IM) SCT.
  5. 05HumanNon-randomized trialPharmacokinetics

    In normal subjects, inhaled calcitonin had 28% of the dose-adjusted bioavailability of intramuscular calcitonin.

    In plain wordsIn normal subjects, inhaled calcitonin had lower availability per dose than injected calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseRelative bioavailability
    Study

    n: not reported in source

    Comparator
    intramuscular salmon calcitonin
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intrapulmonaryAs given in this study (human).

    Measurements

    Relative bioavailability
    28%
    versus IM

    Source sentences

    Summary
    Compared by dose, IP SCT had 66% of the bioactivity and 28% of the bioavailability of IM SCT.
    3 context sentences
    Summary · context
    We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects.
    Summary · context
    SCT was administered with a dry powder delivery inhaler.
    Summary · context
    For comparison, each subject also received intramuscular (IM) SCT.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.